CDX2 Antibody (Rabbit mAb) [B7K17]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:10000 IHC1:1000 IF1:400

Application
WB, IHC, IF

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
34 kDa 40 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CDX2 Antibody (Rabbit mAb) [B7K17] detects endogenous levels of total CDX2 protein.

Clone
B7K17

Synonym(s)
CDX3, CDX2, Homeobox protein CDX-2, CDX-3, Caudal-type homeobox protein 2

Background
CDX2 is an intestine-restricted homeobox transcription factor of the caudal-related family that establishes and maintains intestinal epithelial identity by directly regulating gene networks controlling proliferation, adhesion, and differentiation. It remains expressed in most colorectal carcinomas where it continues to shape lineage-specific programs. CDX2 contains a central homeodomain that binds consensus CDX motifs in promoter and enhancer regions and flanking transactivation domains that interact with components of the transcriptional machinery and chromatin modifiers, allowing CDX2 to act both as an activator of intestinal differentiation genes and as a context-dependent modulator of signaling pathways such as Wnt/β-catenin and PI3K/Akt. In colorectal epithelium, CDX2 directly transactivates key negative regulators of Wnt signaling, including GSK‑3β and Axin2, by binding their promoter or enhancer regions, which increases destruction complex activity, lowers β‑catenin stability and nuclear accumulation, and downregulates β‑catenin targets such as cyclin D1 and c‑Myc, thereby restraining cell-cycle progression and tumor growth. CDX2 knockdown enhances Wnt reporter activity, upregulates these proliferative targets, accelerates G0/G1–to–S transition, and promotes colony formation and tumor growth in xenografts, while CDX2 overexpression has the opposite effects. CDX2 also suppresses epithelial–mesenchymal transition and metastatic behavior by directly activating PTEN transcription, which antagonizes PI3K/Akt signaling, reduces Akt and GSK‑3β phosphorylation, lowers Snail expression, and diminishes β‑catenin stabilization and nuclear translocation, leading to maintenance of epithelial markers and inhibition of EMT drivers. Loss of CDX2 correlates with increased invasion in vitro, enhanced liver metastasis in vivo, and acquisition of EMT phenotypes. Clinical series in colorectal cancer report that CDX2 expression is lost or markedly reduced in a significant subset of tumors and that this loss associates with higher grade, advanced stage, right-sided location, mucinous histology, lymphovascular invasion, and poorer progression-free and overall survival, supporting a role for CDX2 as an independent adverse prognostic factor and as a marker of aggressive, EMT‑prone disease. In the upper gastrointestinal tract, ectopic expression of CDX2 marks intestinal metaplasia in Barrett’s esophagus and is detected in goblet and adjacent columnar cells in most Barrett segments but not in normal gastric-type mucosa, indicating that CDX2 immunostaining provides a sensitive indicator of intestinal differentiation and early metaplastic change in esophageal biopsies, with diagnostic value when goblet cells are sparse or patchy. CDX2 acts as a mechanistically central transcription factor whose DNA-binding and transactivation domains couple developmental cues to intestine-specific gene expression, constrain oncogenic Wnt and PI3K/Akt signaling through direct activation of GSK‑3β, Axin2, and PTEN, and whose loss or misexpression reprograms epithelial behavior toward proliferation, invasion, and metaplasia in colorectal cancer and Barrett’s esophagus.

Background

CDX2 is an intestine-restricted homeobox transcription factor of the caudal-related family that establishes and maintains intestinal epithelial identity by directly regulating gene networks controlling proliferation, adhesion, and differentiation. It remains expressed in most colorectal carcinomas where it continues to shape lineage-specific programs. CDX2 contains a central homeodomain that binds consensus CDX motifs in promoter and enhancer regions and flanking transactivation domains that interact with components of the transcriptional machinery and chromatin modifiers, allowing CDX2 to act both as an activator of intestinal differentiation genes and as a context-dependent modulator of signaling pathways such as Wnt/β-catenin and PI3K/Akt. In colorectal epithelium, CDX2 directly transactivates key negative regulators of Wnt signaling, including GSK‑3β and Axin2, by binding their promoter or enhancer regions, which increases destruction complex activity, lowers β‑catenin stability and nuclear accumulation, and downregulates β‑catenin targets such as cyclin D1 and c‑Myc, thereby restraining cell-cycle progression and tumor growth. CDX2 knockdown enhances Wnt reporter activity, upregulates these proliferative targets, accelerates G0/G1–to–S transition, and promotes colony formation and tumor growth in xenografts, while CDX2 overexpression has the opposite effects. CDX2 also suppresses epithelial–mesenchymal transition and metastatic behavior by directly activating PTEN transcription, which antagonizes PI3K/Akt signaling, reduces Akt and GSK‑3β phosphorylation, lowers Snail expression, and diminishes β‑catenin stabilization and nuclear translocation, leading to maintenance of epithelial markers and inhibition of EMT drivers. Loss of CDX2 correlates with increased invasion in vitro, enhanced liver metastasis in vivo, and acquisition of EMT phenotypes. Clinical series in colorectal cancer report that CDX2 expression is lost or markedly reduced in a significant subset of tumors and that this loss associates with higher grade, advanced stage, right-sided location, mucinous histology, lymphovascular invasion, and poorer progression-free and overall survival, supporting a role for CDX2 as an independent adverse prognostic factor and as a marker of aggressive, EMT‑prone disease. In the upper gastrointestinal tract, ectopic expression of CDX2 marks intestinal metaplasia in Barrett’s esophagus and is detected in goblet and adjacent columnar cells in most Barrett segments but not in normal gastric-type mucosa, indicating that CDX2 immunostaining provides a sensitive indicator of intestinal differentiation and early metaplastic change in esophageal biopsies, with diagnostic value when goblet cells are sparse or patchy. CDX2 acts as a mechanistically central transcription factor whose DNA-binding and transactivation domains couple developmental cues to intestine-specific gene expression, constrain oncogenic Wnt and PI3K/Akt signaling through direct activation of GSK‑3β, Axin2, and PTEN, and whose loss or misexpression reprograms epithelial behavior toward proliferation, invasion, and metaplasia in colorectal cancer and Barrett’s esophagus.

References
https://pubmed.ncbi.nlm.nih.gov/33239678/ https://pubmed.ncbi.nlm.nih.gov/30631044/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%